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The presence of serum autoantibodies in periodontitis (P) patients against β1-adrenoceptor (β1-AR), using cardiacmembranes or a
synthetic β1-AR peptide corresponding to the second extracellular loop of human β1-AR as antigens, permit us to detect circulating
antibody from 40 P patients but not in 20 normal individuals (control). Simultaneously, the P patients exhibited a decrease in HRV.
Anti-β1-AR IgG titters correlated with the decrease in HRV of the same patients and the anti-β1-AR peptide IgG displayed partial
agonist-like activity and modified the contractility of isolated atria, produced cyclic nucleotides, and inhibited the β1-AR agonistic
activity of isoproterenol. We demonstrated in this study an association between periodontitis infection and an increased risk of
cardiac disease, thereby highlighting the role of anti-β1-AR autoantibodies in alteration of myocardial contractility.
1. Introduction
Cardiovascular disease occurs as a result of a complex set of
genetic and environmental factors [1]. Although the identity
of the traditional risk factors has been established, they do
not fully account for the risk of cardiovascular disease, sug-
gesting that other mechanisms contribute to the pathogenic
process [2]. Recently, several lines of evidence have impli-
cated chronic inflammation in the etiology of cardiovascular
disease [3].
Periodontitis is an inflammatory disease of tooth-sup-
porting structures that leads to the destruction of connective
tissue, loss of periodontal attachment, and resorption of
alveolar bone [4].
The pathogenesis of the disease involves essential im-
munological factors associated with infections caused by
bacteria into subgingival plaque [5]. Among the immuno-
logical factors, local synthesis of biological products (e.g.,
enzymes produced by cells of the supporting tissue) as well as
bacterial-specific secretion of immunoglobulin (Ig), soluble
inflammatory mediators, and/or cellular/tissue degradation
products has been described [6–9]. It has been shown that
endotoxins of plaque microorganisms penetrate gingival
tissues and enter the bloodstream in suﬃcient numbers
to cause a systemic lipopolysaccharide-specific antibody re-
sponse [10].
However, in periodontal disease during the process of
combating bacterial infection, the immune systemmay cause
localized tissue damage and activate the systemic humoral
immune response [11, 12]. Thus, the susceptibility to, and
progression of, the disease is dependent upon not only
the virulence of the microbial pathogens, but also the host
response to regulation of tissue destruction.
Initial studies of autoimmunity in the pathogenesis of
periodontal disease focused on detection of autoantibod-
ies directed towards various self-antigens [13–15], such
as autoantibodies against human gingival fibroblasts [16,
17]. Specifically, these antigingival fibroblast autoantibodies
could interact with β1-ARs exhibiting adrenergic agonistic
activity.
Moreover, autoantibodies with immune reactivity
against β1-ARs of themyocardium have been described in the
sera of patients with diﬀerent cardiomyopathies associated
with infection with parasites and viruses [18–22]. Increasing
evidence indicates that periodontal disease is a risk factor
for cardiovascular disease and stroke [23, 24]. The main
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underlying pathological pathway for cardiomyopathy
associated with periodontal disease is atherosclerosis [2].
Increasing evidence suggests that the progression of athero-
sclerosis arises from a combination of dysfunction and
inflammation of the endothelium. Inflammatory mediators
derived from infected periodontal tissue or periodontopathic
bacteria (or their products) could induce dysfunction of
endothelial cells [2].
We demonstrated that serum autoantibodies from pa-
tients with periodontitis could react with the myocardial
surface and with human β1-ARs. A correlation between the
serum antibodies against myocardial β1-ARs and alteration
in heart rate variability (HRV) could be determined. The
capacity of β1-AR autoantibodies to modify atria contractil-
ity in vitro was also assessed.
2. Patients and Methods
2.1. Patients. The study group consisted of 40 male patients
(mean age: 41 years; range: 32–50 years) with periodontitis
attending periodontology clinics in the metropolitan area of
Buenos Aires. Twenty healthy male subjects (mean age: 38
years; range: 30–46 years) were used as controls. The char-
acteristic signs of periodontitis included the following: loss
of clinical attachment; horizontal or/and angular alveolar
bone loss; periodontal pocket formation; gingival inflam-
mation. To be included in the study, at least six sites with
ongoing periodontal disease were required. Measurements
in patients with periodontitis included sites with alveolar
bone loss >2mm and pocket depth >5mm with bleeding
and attachment loss >3mm. In healthy subjects (control
group), the probing depth was <3mm and attachment loss
was <2mm. None of the subjects (patients in group I
and controls in group II) had systemic illnesses and they
were not smokers. Patients had not received periodontal
treatment or antibiotics within the preceding 5 months or
anti-inflammatory drugs 3 weeks before the study. Also, it
can be seen in Tables 1 and 2 the general characteristic of the
study populations and selection index. All patients consented
to participate in the study. The investigation was conducted
according to the tenets of the Declaration of Helsinki.
2.2. HRV. The 20 patients with periodontitis and 20 normal
subjects were studied according to a previous report [25].
Heart rate was recorded using an Oxford Medilog 2–24
miniature analog tape recorder (Oxford InstrumentsMedical
Systems, Abingdon, UK). The recording speed was 2mms−1.
HRV was assessed from RR-interval files generated from
10 pm to 8 am analyzed in hourly epochs. The summary
time-domain statistical measures of HRV calculated included
the HRV long-term standard deviation of all NN (SDNN)
indices. These indices represent variability over heart cycles
and estimate high-frequency variation in the heart rate [25].
2.3. Human Sera and IgG Purification. Sera and the corre-
sponding IgG were obtained from patients with periodontitis
(group I) and from normal individuals (group II). Six
milliliters of blood were obtained by venipuncture. Blood
samples were allowed to clot at room temperature. The
serum was separated by centrifugation at 2000× g and
stored at −20◦C until used in assays. IgG was obtained by
precipitation followed previous reports [17, 18].
2.4. Purification of Antipeptide Antibodies by Aﬃnity Chro-
matography. The IgG fraction of group-I patients was
independently subjected to aﬃnity chromatography on the
synthesized peptide covalently linked to Aﬃ-Gel 15 (Bio-
Rad, Richmond, CA, USA). The IgG fraction was loaded
on the aﬃnity column equilibrated with phosphate-buﬀered
saline (PBS) according to previous reports [16, 17].
2.5. Membrane Preparation. Cardiac membranes from male
rat Wistar strain were prepared as previously described
[17, 18]. In brief, cells or atria were homogenized in an
Ultra-Turrax homogenizer (IKA, Wilmington, NC, USA) at
4◦C in 6 volumes of potassium phosphate buﬀer, 1mM
MgCI2, 0.25M sucrose (pH 7.5) supplemented with 0.1mM
phenylmethyl sulphonyl fluoride (PMSF), 1mM ethylenedi-
amine tetra-acetic acid (EDTA), 5 μg mL−1 leupeptin, 1 μM
bacitracin, and 1 μM pepstatin A. The homogenate was
centrifuged twice for 10min at 3000×g, then at 10,000×g
and 40,000×g at 4◦C for 15min and 90min, respectively.
The resulting pellets were suspended in 50mM phosphate
buﬀer fortified with the same protease inhibitors (pH 7.5).
2.6. ELISA Assay. Fifty micromililiters of peptide solution
at 50 μg/mL concentration or purified cardiac membranes
(50 μg/mL) in 0.1M Na2CO3 buﬀer (pH 9.6) were used to
coat microtiter plates at 4◦C overnight. After blocking the
wells with 2% bovine serum albumin in PBS for 1 h at 37◦C,
10 μL of a 1/30 dilution of sera of diﬀerent concentrations or
purified IgG from groups I and II were added in triplicate
and allowed to react with the peptide for 2 h at 37◦C. After
thoroughly washing the wells with 0.05% Tween 20 in PBS,
100 μL of 1 : 6000 goat anti-human IgG alkaline phosphate
conjugate antibodies were added and incubated for 1 h
at 37◦C. After extensive washing, p-nitrophenylphosphate
(1mg/mL) was added as the substrate and the reaction
stopped after 30min. Optical density (OD) was measured
at 405 nm with an ELISA reader. As a negative control,
nonantigen paired wells with M1 cholinergic peptide and
wells with no primary antiserum were also used. The results
for each sample were expressed as the mean± standard error
of the mean (s.e.m.) of triplicate values.
2.7. Contractile Study. Male rats Wistar strain (200–250 g)
were decapitated and atria quickly removed. Atria were
placed in a glass chamber containing Krebs–Ringer bicar-
bonate (KRB) solution (pH 7.4) that was gassed with 5%
CO2 in oxygen at 30◦C. After a stabilization period of 30min,
spontaneous tension and frequency were recorded using a
force transducer coupled to an ink-writing oscillograph, as
previously described [18].
2.8. Assays for Cyclic Adenosine Monophosphate (cAMP) and
Cyclic Guanosine Monophosphate (cGMP). Rat atria (10mg)
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Table 1: Characteristic of the study populations.
Demography and risk factors Periodontitis patients group I (n = 40) Healthy subjects group II (n = 20)
Gender
Male 36 18
Female 4 2
Education level
Elementary school 38 18
High school 2 2
BMI (range kg/m2) From 20 to 25 From 19 to 22
Measure blood pressure (mmHg)
Measure SBP (mean ± SD) 138 ± 20 118 ± 14
Measure DBP (mean ± SD) 87 ± 12 75 ± 10
Laboratory examination
Cholesterol total (mean ± SD), mg/dl 170 ± 21 176 ± 22
LDL (mean ± SD), mg/dl 129 ± 14 130 ± 21
HDL (mean ± SD), mg/dl 34 ± 10 32 ± 11
BMI: Body Mass Index (range ≥27 kg/m2); SBP: Systolic Blood Pressure. DBP: Diastolic Blood Pressure; LDL: Low-density lipoprotein; HDL: High-density
lipoprotein.
Table 2: Periodontitis selection index.
Parameters Numerical ranges
PPD ≥6mm
CAL ≥6mm
PPD: pocket probing depth; CAL: clinical attachment loss.
were incubated in 1mL KRB for 30min and the β1 agonist
isoproterenol (ISO) added in the last 15min. When blockers
were used, they were added 25min before the addition
of ISO. After incubation, atria were homogenized in 2mL
of absolute ethanol and centrifuged at 6000×g for 15min
at 4◦C. Pellets were then rehomogenized in ethanol-water
(2 : 1). Supernatants were collected and evaporated to dry-
ness as described above. Cyclic AMP or cyclic GMP in the
residue was dissolved in 400 μL of 0.05M sodium acetate
buﬀer (pH 6.2). For determination of nucleotides, we used
ELISA employing the protocol of production of cAMP and
cGMP from Amersham Biosciences (Piscataway, NJ, USA).
Results were expressed in pico moles per milligram of wet
weight of tissue (pmol/mg tissue ww).
2.9. Drugs. Stock solutions of ISO and atenolol were freshly
prepared before each experiment. The β1 peptide corre-
sponded to the sequence of the second extracellular loop
of the human β1-AR (HWWRA ESDEA RRCYN DPKCC
DFVTN RC). An unrelated peptide derived from the sec-
ond extracellular loop of the human M2 cholinoreceptor
(VRTVE DGECY IQFFS NAAVT FGTA) was used as a
control. Radioactive material, synthetic peptides, and β-
adrenergic antagonists were from Dupont/New England
Nuclear (Boston, MA, USA), Sigma Genosys (St. Louis, MO,
USA), and Sigma-Aldrich (St. Louis, MO, USA), respectively.
2.10. Statistical Analysis. The Student’s t-test for unpaired
values was used to determine the levels of significance.
Analysis of variance (ANOVA) and a post hoc test (Dunnett’s
method and Student-Newman-Keuls test) were employed
when pairwise multiple comparison procedures were neces-
sary. Diﬀerences between means were considered significant
if P < 0.05.
3. Results
ELISA assays were carried out to demonstrate if there was a
correlation between the level of IgG in the serum of patients
with periodontitis and cardiac membranes and the β1-AR.
Figure 1 shows the OD values for sera from patients with
periodontitis (group I) and normal subjects (group II) using
rat cardiac membrane (a) and β1-AR synthetic peptide (b) as
coating antigens. The OD values obtained from group-I sera
were alwaysmore than two standard deviations (>2 SD) from
those of normal individuals. Figure 1(c) shows a positive
correlation between serum anticell cardiac membrane and
anti-β1-AR peptide antibodies of the individual sera from
group I. It was noted that 34/40 (85%) and 32/40 (80%) of
patients’ sera reacted positively against cardiac membranes
and β1-AR synthetic peptide, respectively. When unrelated
synthetic peptide (M2 cholinoceptor peptide) was used as a
coating antigen, IgG from group I and from group II gave
negative results (data not shown).
Knowing that the β1-AR is involved in regulating various
cardiac parameters (including heart rate and HRV), we
evaluated the HRV in 20 patients with periodontitis whose
sera reacted positively against β1 synthetic peptide and in 20
normal individuals who acted as controls. The diﬀerences
between patients with periodontitis and normal subjects
with respect to the SDNN index are shown in Figure 2(a).
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Figure 1: Immunoreactivity of circulating IgG antibodies against cardiac membrane (a) or against β1-AR synthetic peptide (b). The optical
density (OD) for serum sample (1/30 dilution) from 40 periodontitis patients (group I) or 20 normal individuals (group II) were evaluated by
duplicate. Values are mean± SD. Cutoﬀ values of OD 0.180 and 0.210 for cardiac membranes and anti-β1-AR synthetic peptide, respectively.
Correlation (c) between titers of serum anti-β1-AR peptide IgG and anticardiac membrane IgG from periodontitis patients. Anti-β1-AR
peptide IgG titters were plotted as function of anti cardiac membranes. The values correspond to 40 periodontitis patients.
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Figure 2: (a) Heart rate variability long-term standard deviation (SDNN) index in 20 patients with periodontitis (group I) and in 20 normal
individuals (group II). (b) Correlation between values of the SDNN index and titers of serum anti-β1-AR peptide IgG. The SDNN index was
plotted as a function of serum titers of anti-β1-AR peptide IgG corresponding to the same patients.
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Table 3: Influence of β1 blockade on the stimulatory and inhibitory eﬀects of anti-β1-AR peptide IgG.
Addition dF/dt cAMP cGMP
Basal 1.8 ± 0.21 0.38 ± 0.03 0.041 ± 0.004
β1-AR IgG (5 × 10−8 M) 3.9 ± 0.32∗ 1.25 ± 0.11∗ 0.051 ± 0.004
β1-AR IgG (5 × 10−8 M) + atenolol 2.1 ± 0.19∗∗ 0.41 ± 0.04∗∗ —
β1-AR IgG + β1-AR peptide 2.3 ± 0.23∗∗ 0.42 ± 0.03∗∗ —
Normal IgG (5 ×10−8 M) 1.9 ± 0.18 0.40 ± 0.02 0.039 ± 0.04
Basal 2.1 ± 0.22 0.40 ± 0.03 0.042 ± 0.004
β1-AR IgG (5 ×10−7 M) 0.6 ± 0.05∗ 0.21 ± 0.02∗ 0.350 ± 0.03∗
β1-AR IgG (5 ×10−7 M) + atenolol 1.7 ± 0.15∗∗ 0.38 ± 0.03∗∗ 0.122 ± 0.02∗∗
β1-AR IgG + β1-AR peptide 1.9 ± 0.20∗∗ 0.37 ± 0.02∗∗ 0.101 ± 0.02∗∗
Normal IgG (5 ×10−7 M) 2.0 ± 0.19 0.42 ± 0.03 0.043 ± 0.003
Values are mean ± s.e.m. of ten patients with periodontitis in each group carried out in duplicate. Contractility (dF/dt: g/s), and levels of cAMP (pmol/mg
tissue ww) and cGMP (pmol/mg tissue ww) were measured after incubation for 15min with rat atria in the presence of anti-β1-AR peptide IgG (β1-AR IgG)
and normal IgG or in the absence (basal) of IgG. Atenolol (5×10−7 M) and β1-AR peptide (5×10−5 M) were added before the IgG. ∗P < 0.001 versus basal;
∗∗P < 0.001 versus β1-AR IgG alone.
There was a significant decrease in HRV (mean ± SD: 65.1 ±
9.2) in patients with periodontitis in comparison with the
control group (mean ± SD: 90.3 ± 10). When the SDNN
index was plotted as a function of serum titers, anti-β1-AR
peptide IgG from each patient with periodontitis showed
a negative correlation between serum anti-β1-AR peptide
antibodies and the SDNN index (Figure 2(b)).
We observed that patients with periodontitis showed a
profound alteration in cardiac contractility in vivo, so we
wanted to ascertain if serum anti-β1-AR antibodies could
trigger cardiac β1-AR functional alterations in atria. For this
purpose, we selected the 20 patients with periodontitis who
showed a decrease in HRV and whose sera were positive
against β1-adrenergic synthetic peptide in the ELISA assay.
The IgG fraction was independently subjected to aﬃnity
chromatography and eluted from the column covalently
linked to β1-adrenergic synthetic peptide (anti-β1-AR pep-
tide IgG). Increasing concentrations of anti-β1-AR peptide
IgG were applied to isolated spontaneously beating rat
atria and changes in the magnitude of contractility (dF/dt)
measured (Figure 3).
Anti-β1-AR peptide IgG behaved as a partial β1-adren-
ergic agonist; increasing dF/dt at low concentrations and at
higher concentrations, autoantibodies decreased dF/dt (Fig-
ures 3(a) and 3(b)). The stimulatory and inhibitory eﬀects
were accompanied by modification of cAMP production
(Figure 3(a)) and cGMP production (Figure 3(b)). cAMP
production correlated positively with the stimulatory eﬀect
of the antibodies (Figure 3(c)), but cGMP production cor-
related negatively with the inhibitory eﬀect of the antibodies
(Figure 3(d)). Table 3 shows the eﬀect of blockade upon the
eﬀect of IgG on dF/dt, cAMP and cGMP. For the β1-AR,
the stimulatory and inhibitory eﬀects were almost abolished
by pretreatment of atria with 1 × 10−7 M atenolol (β1-
AR antagonist) and by 1 × 10−5 M β1-adrenergic synthetic
peptide. The IgG from normal subjects and the nonpeptide
fraction gave negative results (data not shown).
To ascertain if anti-β1-AR peptide IgG interacted with the
same cardiac β1-AR epitope as an authentic agonist (ISO), we
studied the action of anti-β1-AR peptide antibody upon ISO.
Themaximal positive eﬀects of 5× 10−8 M ISO on dF/dt (g/s:
5.3± 0.5, n = 5) and the cAMP stimulation (pmol/mg tissue
ww: 2.8± 0.3, n = 5) were blunted by 5×10−7 M anti-β1-AR
peptide IgG.
4. Discusion
We previously demonstrated that patients with periodontitis
have functional serum IgG that interacts with the β1-AR
of gingival fibroblasts. In the present study, we confirmed
the presence of anti-β1-AR autoantibodies in the sera of
patients with periodontitis and provided evidence that
these sera can also recognize the cardiac membranes of
rats. Most of the sera that reacted positively against rat
cardiac membranes showed positive immune reactivity to
human β1-AR synthetic peptide. Furthermore, a significant
correlation between anticardiac membrane antibodies and
anti-β1-AR peptide IgG was observed.
Using a synthetic peptide with an identical amino acid
sequence of the second extracellular loop of human β1-AR,
we established that the β1-AR is a target for the anticardiac
autoantibodies described in patients with periodontitis. Due
to the strong homology between rodent and human β1-
AR peptides [26], one can assume that this is the one
recognized by the autoantibodies. It has been shown that
the second extracellular loop of cardiovascular G-protein-
coupled receptors is an antigenic target for the generation
of autoantibodies in patients with cardiomyopathy [27].
Therefore, we studied the β1-AR-mediated eﬀect of autoanti-
bodies on isolated rat atria using aﬃnity-purified anti-β1-AR
peptide IgG from patients with periodontitis.
HRV is a powerful predictor of cardiovascular mortal-
ity in healthy people, those who have had a myocardial
infarction, and in patients with heart failure. An elevated
resting heart rate, reduced HRV, or both are negative
prognostic factors independent of other clinical parameters,
including left ventricular function [28]. Impaired control
of HRV is linked to a deleterious sympathovagal imbalance
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Figure 3: Eﬀect of increasing concentrations of anti-β1-AR peptide IgG (IgG) on contractility (dF/dt) and production of cAMP and cGMP in
isolated atria from rats. (a) Comparative eﬀects of anti-β1-AR peptide IgG on dF/dt (•-•) and on cAMPproduction (©-©). (b) Comparative
eﬀects of anti-β1-AR peptide IgG on dF/dt (•-•) and on cGMP production (©-©). (c) Positive correlation between cAMP and dF/dt
(corresponding data to A values). (d) Negative correlation between cGMP and dF/dt (corresponding data to B values). Values are mean ±
s.e.m. of 20 patients with periodontitis.
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characterized by predominance of the sympathetic nervous
system [28].
In the present study, the finding of a correlation between
decrease in HRV and the presence of serum anticardiac
membrane autoantibodies and anti-β1-AR autoantibodies
in patients with periodontitis allows us to suggest that the
lower HRV observed in such patients is due to fixation of
antibodies upon receptors. HRV alteration may be a conse-
quence of activation of the β1-AR induced by antibody β1-AR
interaction on the cardiac sarcolemma.
We also provide evidence that isolated fractions of
IgG enriched in anti-β1-AR peptide antibody could display
partial agonistic activity on contractility in isolated atria.
The partial agonistic activity of autoantibodies observed
in vitro mimics the action on HRV of the partial β1-
adrenergic agonist celiprolol described in vivo. However, the
combination of celiprolol with atenolol did not prevent the
fall in HRV triggered by the partial agonist [25]. Hence,
the antibody-mediated partial β1 agonistic activity could
be responsible for the decrease in HRV in patients with
periodontitis.
The increase in contractility observed at low concen-
trations of IgG correlated with the increase in production
of cAMP, whereas the decrease in contractility triggered by
higher concentrations of IgG correlated with an increase in
cGMP production. The increase and decrease in contractility
are related to β1-AR function because they were blunted
by atenolol. The increase in cGMP production which could
limit the increase in contractility of β-adrenergic stimulation
of isolated rat atria has been established [29].
The interaction of anti-β1-AR autoantibodies with the
receptor has two functional implications: (i) it directly
modifies the sympathetic activity of the myocardium; (ii) it
decreases the eﬀectiveness of the authentic agonist ISO. This
raises the question: could there be a common explanation
for the abnormal sympathetic activity in the cardiovascular
system mediated by cardiac β1-AR autoantibodies? If so,
antibody fixation could increase sympathetic activity for
an extended period and result in a chronically elevated
heart rate. Simultaneously, the antagonistic activity of the
autoantibodies could lead to deleterious sympathovagal
imbalance, resulting in functional deregulation associated
with pathologic remodelling, myocyte apoptosis, and alter-
ation of calcium handling that leads to myocardial ischemia,
a decrease in contractile function, and an increased risk of
ventricular arrhythmias [30].
Acknowledgments
This work was supported by Grants from Buenos Aires
University (UBACyT O 017) and the Argentine Research and
Technology Agency (BID 2006-PICT 01647). The authors
thank Mrs. Elvita Vannucchi for her expert technical assis-
tance.
Conflict of Interests
There are no competing interests.
References
[1] K. Karnoutsos, P. Papastergiou, S. Stefanidis, and A.
Vakaloudi, “Periodontitis as a risk factor for cardiovascular
disease: the role of anti-phosphorylcholine and anti-cardiol-
ipin antibodies,”Hippokratia, vol. 12, no. 3, pp. 144–149, 2008.
[2] T. Nakajima and K. Yamazaki, “Periodontal disease and risk
of atherosclerotic coronary heart disease,” Odontology, vol. 97,
no. 2, pp. 84–91, 2009.
[3] L. L. Humphrey, R. Fu, D. I. Buckley, M. Freeman, and
M. Helfand, “Periodontal disease and coronary heart disease
incidence: a systematic review and meta-analysis,” Journal of
General Internal Medicine, vol. 23, no. 12, pp. 2079–2086,
2008.
[4] H. Toker, I. Marakoglu, and O. Poyraz, “Eﬀect of meloxicam
on gingival crevicular fluid IL-1beta and IL1 receptor antago-
nist levels in subjects with chronic periodontitis, and its eﬀects
on clinical parameters,”Clinical Oral Investigations, vol. 10, no.
4, pp. 305–310, 2006.
[5] M. A. Listgarten and P. M. Loomer, “Microbial identification
in the management of periodontal diseases. A systematic re-
view,” Annals of Periodontology, vol. 8, no. 1, pp. 182–192,
2003.
[6] J. Gamonal, A. Acevedo, A. Bascones, O. Jorge, and A.
Silva, “Levels of interleukin-1β, -8, and -10 and RANTES
in gingnival crevicular fluid and cell populations in adult
periodontitis patients and the eﬀect of periodontal treatment,”
Journal of Periodontology, vol. 71, no. 10, pp. 1535–1545, 2000.
[7] A. Holmlund, L. Ha¨nstro¨m, andU.H. Lerner, “Bone resorbing
activity and cytokine levels in gingival crevicular fluid before
and after treatment of periodontal disease,” Journal of Clinical
Periodontology, vol. 31, no. 6, pp. 475–482, 2004.
[8] P. A. Heasman, J. G. Collins, and S. Oﬀenbacher, “Changes
in crevicular fluid levels of interleukin-1 beta, leukotriene
B4, prostaglandin E2, thromboxane B2 and tumour necrosis
factor alpha in experimental gingivitis in humans,” Journal of
Periodontal Research, vol. 28, no. 4, pp. 241–247, 1993.
[9] I. B. Lamster, R. L. Oshrain, R. S. Celenti, J. B. Fine, and J.
T. Grbic, “Indicators of the acute inflammatory and humoral
immune responses in gingival crevicular fluid: relationship
to active periodontal disease,” Journal of Periodontal Research,
vol. 26, no. 3, pp. 261–263, 1991.
[10] E. Hernichel-Gorbach, K. S. Kornman, S. C. Holt et al., “Host
responses in patients with generalized refractory periodonti-
tis,” Journal of Periodontology, vol. 65, no. 1, pp. 8–16, 1994.
[11] C. A. Ramseier, J. S. Kinney, A. E. Herr et al., “Identification
of pathogen and host-response markers correlated with peri-
odontal disease,” Journal of Periodontology, vol. 80, no. 3, pp.
436–446, 2009.
[12] H. A. Schenkein, “Host responses in maintaining periodontal
health and determining periodontal disease,” Periodontology
2000, vol. 40, no. 1, pp. 77–93, 2006.
[13] C. G. Dileep Sharma and A. R. Pradeep, “Anti-neutrophil cyto-
plasmis autoantibodies: a renewed paradigm in periodontal
disease pathogenesis?” Journal of Periodontology, vol. 77, no.
8, pp. 1304–1313, 2006.
[14] P. S. Rajapakse and A. E. Dolby, “Evidence for local production
of antibodies to auto and non-self antigens in periodontal
disease,” Oral Diseases, vol. 10, no. 2, pp. 99–105, 2004.
[15] L. A. De-Gennaro, J. D. Lopes, and M. Mariano, “Autoanti-
bodies directed to extracellular matrix components in patients
with diﬀerent clinical forms of periodontitis,” Journal of Peri-
odontology, vol. 77, no. 12, pp. 2025–2030, 2006.
ISRN Dentistry 9
[16] L. Sterin-Borda, C. Furlan, and E. Borda, “Circulating beta
1 adrenergic auto antibodies from patients with chronic
periodontitis interact with gingival fibroblasts,” European
Journal of Dentistry, vol. 3, pp. 191–199, 2009.
[17] L. Sterin-Borda, C. Furlan, and E. Borda, “Autoantibodies
to β1-adrenoceptors in human chronic periodontitis induce
overexpression of fibroblast CD40 and trigger prostaglandin
E2 generation,” Journal of Periodontal Research, vol. 44, no. 3,
pp. 330–337, 2009.
[18] L. Sterin-Borda, G. Gorelik, M. Postan, S. Gonzalez Cappa,
and E. Borda, “Alterations in cardiac beta-adrenergic recep-
tors in chagasic mice and their association with circulat-
ing beta-adrenoceptor-related autoantibodies,”Cardiovascular
Research, vol. 4, no. 4, pp. 116–125, 1970.
[19] L. Joensen, E. Borda, T. Kohout, S. Perry, G. Garcı´a, and
L. Sterin-Borda, “Trypanosoma cruzi antigen that interacts
with the β1-adrenergic receptor and modifies myocardial
contractile activity,” Molecular and Biochemical Parasitology,
vol. 127, no. 2, pp. 169–177, 2003.
[20] L. Sterin-Borda and E. Borda, “Role of neurotransmitter
autoantibodies in the pathogenesis of chagasic peripheral
dysautonomia,” Annals of the New York Academy of Sciences,
vol. 917, pp. 273–280, 2000.
[21] E. Borda, J. Pascual, and P. Cossio, “A circulating IgG in Cha-
gas’ disease which binds to β-adrenoceptors of myocardium
and modulates their activity,” Clinical and Experimental
Immunology, vol. 57, no. 3, pp. 679–686, 1984.
[22] C. J. Limas, I. F. Goldenberg, and C. Limas, “Autoantibodies
against β-adrenoceptors in human idiopathic dilated car-
diomyopathy,” Circulation Research, vol. 64, no. 1, pp. 97–103,
1989.
[23] W. Nesse, P. U. Dijkstra, F. Abbas et al., “Increased prevalence
of cardiovascular and autoimmune diseases in periodontitis
patients: a cross-sectional study,” Journal of Periodontology,
vol. 81, no. 11, pp. 1622–1628, 2010.
[24] G. R. Persson and R. E. Persson, “Cardiovascular disease and
periodontitis: an update on the associations and risk,” Journal
of Clinical Periodontology, vol. 35, no. 8, pp. 362–379, 2008.
[25] B. Silke and J. G. Riddell, “Heart rate variability eﬀects of
an agonist or antagonists of the β-adrenoceptor assessed
with scatterplot and sequence analysis,” Clinical Autonomic
Research, vol. 8, no. 3, pp. 145–153, 1998.
[26] J. R. Jasper, R. E. Link, A. J. Chruscinski, B. K. Kobika, and
B. Berstein, “Primary structure of the mouse β1-adrenergic
receptor gene,” Biochimica et Biophysica Acta, vol. 178, pp.
307–309, 1993.
[27] M. L. X. Fu, W. Schulze, G. Wallukat, A. Hjalmarson, and J.
Hoebeke, “Functional epitope analysis of the second extra-
cellular loop of the human heart muscarinic acetylcholine
receptor,” Journal of Molecular and Cellular Cardiology, vol. 27,
no. 1, pp. 427–436, 1995.
[28] D. Feldman, T. S. Elton, D. M. Menachemi, and R. K.
Wexler, “Heart rate control with adrenergic blockade: clinical
outcomes in cardiovascular medicine,” Vascular Health and
Risk Management, vol. 6, pp. 387–397, 2010.
[29] L. Sterin-Borda, A. Genaro, C. P. Leiros, G. Cremaschi, A. V.
Echagu¨e, and E. Borda, “Role of nitric oxide in cardiac β-
adrenoceptor-inotropic response,” Cellular Signalling, vol. 10,
no. 4, pp. 253–257, 1998.
[30] M. J. De Jong andD. C. Randall, “Heart rate variability analysis
in the assessment of autonomic function in heart failure,” The
Journal of Cardiovascular Nursing, vol. 20, no. 3, pp. 186–197,
2005.
